Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of CytomX Therapeutics, Inc. The shares are listed…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
